New data for Lucentis® (ranibizumab) has demonstrated improvement in visual acuity achieved with individualized treatment after one year is maintained for up to three years on average in patients with VI-DMO, with fewer injections in years two and three compared to the first year and no additional or new safety risks identified1.The findings come from the RESTORE extension study which showed that patients originally treated with ranibizumab on an individualized basis received an average of 13.9 injections over three years for VI-DMO patients1.In the extension study, 19-25% of patients, across all study arms, did not require any ranibizumab injections during years two and three. An average of 3.7 injections in the second year and 2.7 in the third year across the two ranibizumab arms were sufficient to fully maintain the mean of seven letters of visual acuity1.To see more details visit, www.medicalnewstoday